BCRX250117C1000
- 6.40
- 0.000.00%
BioCryst Pharmaceuticals Newsroom
BioCryst Pharmaceuticals Sees FY25 Rev $540M-$560M >BCRX
Express News | BioCryst Pharmaceuticals: Expects to Approach Quarterly EPS Profitability/Positive Cash Flow in 2H 2025
Express News | BioCryst Pharmaceuticals: New Drug Application Planned in 2025 for Orladeyo Granules in Children up to Age 12
Express News | BioCryst Announces Preliminary Full Year 2024 Orladeyo® (Berotralstat) Net Revenue of $437 Million (+34 Percent Y-O-Y)
Express News | BioCryst Pharmaceuticals Q4 Product Sales USD 123.5 Million
BioCryst Announces Preliminary Full Year 2024 ORLADEYO (Berotralstat) Net Revenue of $437 Million (+34 Percent Y-o-y)
The 8.2% Return This Week Takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) Shareholders Five-year Gains to 194%
Express News | BioCryst Pharmaceuticals Inc - Increases Wholesale Acquisition Cost for Orladeyo to $44,484.33 per 28-Day Pack
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says
KalVista Wins New Buy at BofA on Potential of Lead Candidate
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Institutional Investors Lost 5.5% Last Week but Have Benefitted From Longer-term Gains
Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator
BioCryst Launches ORLADEYO (Berotralstat) in Ireland
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
BioCryst (BCRX) Receives a Buy From Bank of America Securities
When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals | 10-Q: Q3 2024 Earnings Report